Relationship between serum PRDX1 and TSG-6 levels in children with refractory Mycoplasmal pneumoniae pneumonia and the disease condition and prognosis

doi:10.3969/j.issn.1673-8640.2026.08.003

Abstract

Abstract:

Objective To investigate the roles of serum peroxiredoxin 1（PRDX1） and tumor necrosis factor-alpha-stimulated gene 6 protein（TSG-6） levels in the assessment of the severity and prognosis of children with refractory Mycoplasmal pneumoniae pneumonia（RMPP）. Methods A total of 103 children with RMPP（RMPP group），100 children with general Mycoplasmal pneumoniae pneumonia（GMPP）（GMPP group） and 105 healthy children（healthy control group） were enrolled from Hengshui Fourth People's Hospital. The clinical data were collected，and serum PRDX1 and TSG-6 levels were determined. According to the clinical pulmonary infection score（CPIS），the RMPP children were classified into mild（CPIS <6 points） group（59 cases） and severe（CPIS ≥6 points） group（44 cases）. The RMPP children were classified into good prognosis group（68 cases） and poor prognosis group（35 cases）. Spearman correlation analysis was used to evaluate the correlation between serum PRDX1 and TSG-6 and the severity of RMPP. Multivariate Logistic regression analysis was used to evaluate the influencing factors of poor prognosis in RMPP children. Receiver operating characteristic（ROC） curve and decision curve were used to evaluate the efficacy and clinical applicability of single and combined determinations of serum PRDX1 and TSG-6 in judging the poor prognosis of RMPP children. Results The serum PRDX1 and TSG-6 levels in RMPP group were higher than those in healthy control group（P<0.001）. The proportion of lesions≥2 lung lobes and the proportion of large patchy shadows in the lesion type in severe group were higher than those in mild group（P<0.05）. There was no statistical significance in the other indicators between the 2 groups（P>0.05）. Serum PRDX1 and TSG-6 levels were positively correlated with the severity of RMPP（r values were 0.586 and 0.537，respectively，P<0.05）. The proportion of lesions ≥2 lung lobes and the proportion of large patchy shadows in the lesion type in poor prognosis group were higher than those in good prognosis group（P<0.05）. There was no statistical significance in the other indicators between the 2 groups（P>0.05）. Increased serum PRDX1 and TSG-6 were risk factors for poor prognosis in RMPP children [odds ratios（OR） were 2.851 and 2.947，95% confidence intervals（CI） were 1.402-5.796 and 1.508-5.761，P<0.01]. The areas under curves（AUC） of single and combined determinations of serum PRDX1 and TSG-6 in judging the poor prognosis of RMPP children were 0.824，0.840 and 0.923，respectively，and the maximum net yield of combined determination was 1 when the high-risk cut-off value was 0.05-0.83. Conclusions The serum PRDX1 and TSG-6 levels in RMPP children were elevated and are related to the severity and prognosis. They may be biomarkers for assessing the severity and prognosis of RMPP.

Key words: Peroxiredoxin 1, Tumor necrosis factor-alpha-stimulated gene 6 protein, Refractory Mycoplasmal pneumoniae pneumonia, Prognosis

CLC Number:

Q554

CHEN Yun, HU Lijie, WANG Tingting, YE Shengqian. Relationship between serum PRDX1 and TSG-6 levels in children with refractory Mycoplasmal pneumoniae pneumonia and the disease condition and prognosis[J]. Laboratory Medicine, 2026, 41(8): 737-743.

Figures/Tables 8

References 24

[1]	翟斌, 韩梅. 肺炎支原体肺炎患儿血清miR-21、miR-146a表达变化及其与炎症因子的相关性[J]. 检验医学, 2024, 39(8):787-792.
[2]	Chen Y, Jia X, Gao Y, et al. Increased macrolide resistance rate of Mycoplasma pneumoniae correlated with epidemic in Beijing,China in 2023[J]. Front Microbiol, 2024, 15(1):1449511.
[3]	Gao L W, Yin J, Hu Y H, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China:2006 to 2016[J]. Epidemiol Infect, 2019, 147(1):e192.
[4]	Huang X, Huang D, Wang W, et al. Prevalence,risk factors,and early prediction of refractory pneumonia caused by Mycoplasma pneumoniae in children:a systematic review and meta-analysis[J]. Eur J Pediatr, 2026, 185(3):144.
[5]	Ding G, Zhang X, Vinturache A, et al. Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia[J]. Eur J Pediatr, 2024, 183(7):3001-3011.
[6]	Chen Q, Hu T, Wu L, et al. Clinical features and biomarkers for early prediction of refractory Mycoplasma pneumoniae pneumonia in children[J]. Emerg Med Int, 2024, 2024(1):9328177.
[7]	Rhee S G, Woo H A. Multiple functions of 2-Cys peroxiredoxins,Ⅰ and Ⅱ,and their regulations via post-translational modifications[J]. Free Radic Biol Med, 2020, 152(1):107-115.
[8]	Elko E A, Cunniff B, Seward D J, et al. Peroxiredoxins and beyond;redox systems regulating lung physiology and disease[J]. Antioxid Redox Signal, 2019, 31(14):1070-1091.
[9]	Day A J, Milner C M. TSG-6:a multifunctional protein with anti-inflammatory and tissue-protective properties[J]. Matrix Biol, 2019, 78(2):60-83.
[10]	Bryan C, Sammour I, Guerra K, et al. TNFα-stimulated protein 6(TSG-6) reduces lung inflammation in an experimental model of bronchopulmonary dysplasia[J]. Pediatr Res, 2019, 85(3):390-397.
[11]	中华医学会儿科学分会呼吸学组, 中华儿科杂志编辑委员会, 中国医药教育协会儿科专业委员会. 儿童社区获得性肺炎管理指南(2024修订)[J]. 中华儿科杂志, 2024, 62(10):920-930.
[12]	中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 新发传染病电子杂志, 2024, 9(1):73-79.
[13]	Luna C M, Blanzaco D, Niederman M S, et al. Resolution of ventilator-associated pneumonia:prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome[J]. Crit Care Med, 2003, 31(3):676-682.
[14]	中华医学会儿科学分会呼吸学组,《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志, 2015, 30(17):1304-1308.
[15]	Meyer Sauteur P M, Theiler M, Bueffcher M, et al. Frequency and clinical presentation of mucocutaneous disease due to Mycoplasma pneumoniae infection in children with community-acquired pneumonia[J]. JAMA Dermatol, 2020, 156(2):144-150.
[16]	Sun H N, Ren C X, Lee D H, et al. PRDX1 negatively regulates bleomycin-induced pulmonary fibrosis via inhibiting the epithelial-mesenchymal transition and lung fibroblast proliferation in vitro and in vivo[J]. Cell Mol Biol Lett, 2023, 28(1):48-53.
[17]	He Y, Peng Y, Tao L, et al. Peroxiredoxin-1 aggravates lipopolysaccharide-induced septic shock via promoting inflammation[J]. Biochem Biophys Res Commun, 2020, 527(4):861-865.
[18]	Li J, Li P, Yuan S, et al. Pulchinenoside B4 alleviates DSS-induced colitis by inhibiting CD1d-dependent NLRP3 inflammasome activation in macrophages[J]. Int Immunopharmacol, 2025, 148(1):114118-114125.
[19]	Li S, Zhang Y, Lu R, et al. Peroxiredoxin 1 aggravates acute kidney injury by promoting inflammation through Mincle/Syk/NF-κB signaling[J]. Kidney Int, 2023, 104(2):305-323.
[20]	Xu C, Feng C, Huang P, et al. TNFα and IFNγ rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property[J]. Stem Cell Res Ther, 2022, 13(1):491-502.
[21]	Su W, Nong Q, Wu J, et al. Anti-inflammatory protein TSG-6 secreted by BMSCs attenuates silica-induced acute pulmonary inflammation by inhibiting NLRP3 inflammasome signaling in macrophages[J]. Int J Biol Macromol, 2023, 253(3):126651.
[22]	Yang S, Liang X, Song J, et al. A novel therapeutic approach for inflammatory bowel disease by exosomes derived from human umbilical cord mesenchymal stem cells to repair intestinal barrier via TSG-6[J]. Stem Cell Res Ther, 2021, 12(1):315-321.
[23]	Lu B, Xing L, Zhu X Y, et al. Tumor necrosis factor-stimulated gene-6 inhibits endoplasmic reticulum stress in the ischemic mouse kidney[J]. iScience, 2024, 27(12):111454-111462.
[24]	Ding Y, Gong P, Jiang J, et al. Mesenchymal stem/stromal cells primed by inflammatory cytokines alleviate psoriasis-like inflammation via the TSG-6-neutrophil axis[J]. Cell Death Dis, 2022, 13(11):996.

组别	例数	性别		年龄/岁	BMI/ （kg·m^-2）
组别	例数	男/例	女/例	年龄/岁	BMI/ （kg·m^-2）
正常对照组	105	52	53	6.05±0.78	18.63±2.74
GMPP组	100	49	51	6.11±0.64	18.41±3.07
RMPP组	103	55	48	6.24±1.27	18.25±3.86
统计值		0.473		1.111	0.357
P值		0.789		0.330	0.700

组别	例数	性别		年龄/岁	BMI/ （kg·m^-2）
组别	例数	男/例	女/例	年龄/岁	BMI/ （kg·m^-2）
正常对照组	105	52	53	6.05±0.78	18.63±2.74
GMPP组	100	49	51	6.11±0.64	18.41±3.07
RMPP组	103	55	48	6.24±1.27	18.25±3.86
统计值		0.473		1.111	0.357
P值		0.789		0.330	0.700

组别	例数	PRDX1/（ng·mL^-1）	TSG-6/（ng·mL^-1）
正常对照组	105	6.15±1.07	0.48±0.07
GMPP组	100	7.73±1.08^*	0.72±0.11^*
RMPP组	103	9.84±2.43^*#	1.65±0.38^*#
统计值		129.768	732.557
P值		<0.001	<0.001

组别	例数	PRDX1/（ng·mL^-1）	TSG-6/（ng·mL^-1）
正常对照组	105	6.15±1.07	0.48±0.07
GMPP组	100	7.73±1.08^*	0.72±0.11^*
RMPP组	103	9.84±2.43^*#	1.65±0.38^*#
统计值		129.768	732.557
P值		<0.001	<0.001

组别	例数	性别			年龄/岁	BMI/（kg·m^-2）	发病至入院时间/d		居住环境
组别	例数	男/[例（%）]		女/[例（%）]	年龄/岁	BMI/（kg·m^-2）	发病至入院时间/d		乡镇/[例（%）]		城市/[例（%）]
轻症组	59	32（54.24）		27（45.76）	6.18±0.75	18.17±1.95	2.25±0.34		24（40.68）		35（59.32）
重症组	44	23（52.27）		21（47.73）	6.32±0.79	18.36±2.03	2.37±0.39		20（45.45）		24（54.55）
统计值		0.039			0.909	0.478	1.630		0.235
P值		0.843			0.366	0.634	0.106		0.628
组别	早产儿/ [例（%）]		先天性气道发育异常/[例（%）]	病变范围			病变类型			PRDX1/（ng·mL^-1）	TSG-6/（ng·mL^-1）
组别	早产儿/ [例（%）]		先天性气道发育异常/[例（%）]	单肺叶/ [例（%）]	≥2个肺叶/[例（%）]		大片状阴影/[例（%）]	云絮状或斑片状阴影/[例（%）]		PRDX1/（ng·mL^-1）	TSG-6/（ng·mL^-1）
轻症组	8（13.56）		4（6.78）	34（57.63）	25（42.37）		30（50.85）	29（49.15）		8.79±1.04	1.51±0.17
重症组	5（11.36）		2（4.55）	9（20.45）	35（79.55）		34（77.27）	10（22.73）		11.25±1.36	1.86±0.21
统计值	0.110		0.003	14.321			7.481			10.009	9.058
P值	0.740		0.957	<0.001			0.006			<0.001	<0.001